GLP-1 has opposing effects on hepatic lipid accumulation and plasma lipid levels, which has recently broadened its clinical use in pharmacological therapy of metabolic syndrome and steatohepatitis8,9. This evidence concerns the gene GCG and metabolic syndrome.